# Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia

> **NCT00206960** · NA · COMPLETED · sponsor: **Birte Glenthoj** · enrollment: 56 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** zuclopenthixol
- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00206960
- **Lead sponsor:** Birte Glenthoj
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-01
- **Primary completion:** 2010-09
- **Final completion:** 2010-09
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2011-09-19

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00206960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00206960, "Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00206960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*